Results 161 to 170 of about 2,682 (215)

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Multiple Effects of SGLT2 Inhibitors

JMA Journal
openaire   +2 more sources

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

Journal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür, Emin Koyun, Gülşen Genç Tapar, Kayıhan Karaman, Metin Karayakali, Ataç Çelik, Uğur Kulu, Yasin Taşkin   +7 more
wiley   +1 more source

Characterization of AF Recurrence and Substrate Health by Electrographic Flow (EGF) Consistency in EGF Mapping

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Electrographic flow (EGF) mapping is an FDA 510(k)‐cleared method for visualizing atrial activation wavefronts in atrial fibrillation (AF). Its clinical efficacy in detecting AF sources was demonstrated in the FLOW‐AF randomized controlled trial, and the underlying machine learning strategy used to develop and refine EGF source ...
Steven Castellano, Marloes Jansen, Lucas V. A. Boersma, Marisa van der Graaf, Melissa H. Kong, Kostiantyn Ahapov, Philip Haeusser, Moritoshi Funasako, John D. Hummel, Wilber W. Su   +9 more
wiley   +1 more source

Time‐Dependent Accrual of Cardiorenal Benefit With SGLT2 Inhibitors in Chronic Kidney Disease: A Reconstructed Individual Patient Data Meta‐Analysis of Randomized Trials

Diabetes, Obesity and Metabolism, EarlyView.
Shotaro Yoshida, Mashiro Iwatsubo, Takahiro Nakamura, Makiko Oda, Yusuke Sakamaki   +4 more
wiley   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice

Journal of Diabetes Investigation, EarlyView.
Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan, Tian‐Rong Li, Jing‐Jing Yang, Xiao‐Lu Li, Wen‐Qin Li, Jin‐Wen Yu   +5 more
wiley   +1 more source

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, EarlyView.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

Developing a machine learning model to predict renal function decline within three years using one‐year longitudinal data in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
We developed a machine learning model to predict renal function decline in patients with type 2 diabetes and preserved kidney function. Using one year of routine clinical data, the model forecasts eGFR decline over three years, enabling early identification of high‐risk patients and supporting timely, targeted therapeutic interventions.
Mari Kaneda, Shu Meguro, Kaiken Kimura, Youichiro Harada, Makoto Enomoto, Kaori Hayashi   +5 more
wiley   +1 more source